| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10208299 | AMICUS THERAP US | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278599 | AMICUS THERAP US | High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
Mar, 2033
(8 years from now) | |
| US10512677 | AMICUS THERAP US | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
Mar, 2033
(8 years from now) | |
| US11753632 | AMICUS THERAP US | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Sep, 2035
(11 years from now) | |
| US10961522 | AMICUS THERAP US | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Sep, 2035
(11 years from now) | |
| US11278601 | AMICUS THERAP US | Augmented acid alpha-glucosidase for the treatment of Pompe disease |
Dec, 2036
(12 years from now) | |
| US10857212 | AMICUS THERAP US | Augmented acid alpha-glucosidase for the treatment of Pompe disease |
Aug, 2037
(13 years from now) | |
Opfolda is owned by Amicus Therap Us.
Opfolda contains Miglustat.
Opfolda has a total of 7 drug patents out of which 0 drug patents have expired.
Opfolda was authorised for market use on 28 September, 2023.
Opfolda is available in capsule;oral dosage forms.
Opfolda can be used as the treatment of pompe patients.
The generics of Opfolda are possible to be released after 12 August, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2026 |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 28 September, 2023
Treatment: The treatment of pompe patients
Dosage: CAPSULE;ORAL
More Information on Dosage
OPFOLDA family patents
